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Abstract
AIM
To investigate interferon-γ-inducible protein-10’s (IP-10) 
potential to anticipate rapid (RVR)- and sustained 
virological responses (SVR) to chronic hepatitis C (CHC) 
treatment.
METHODS
We included case series examining RVR or SVR in relation 
to 24 or 48 wk treatment for CHC, in patients treatment 
free for at least six months, with genotype 1 or 4, and 
in relation to 24 wk treatment for genotype 2 and 3, 
with pegylated interferon in combination with ribavirin. 
Patients had to have both a baseline IP-10 level as well 
as a hepatitis C virus (HCV)-RNA determination 4 wk 
after treatment initiation or 24 wk after end of treatment. 
Studies including patients with liver diseases other than 
CHC, human immunodeficiency virus-infection, treatment 
with immunosuppresents or cytostatica, alcohol dependency 
or active intravenous drug-use were excluded. We found 
81 articles by searching the MEDLINE and EMBASE 
databases. Eight studies were eligible for inclusion. Their 
quality were assesed using an 18 point checklist for case 
series, developed using a modified Delphi technique. 
Information was extracted from the articles, and no 
raw data was requisitioned. The review protocol was 
Submit a Manuscript: http://www.f6publishing.com
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registered at the International Prospective Register of 
Systematic Reviews (reg. number: CRD42014008736).
RESULTS
Three studies reported on baseline IP-10 level in asso-
ciation with RVR. A signigficant association was found 
for HCV genotype 1 infection by two studies. Only 
two studies reported on HCV genotype 4 infected and 
genotype 2 and 3 infected patients, respectively. A trend 
was seen for an association between RVR and baseline 
IP-10 for genotype 4, while no association was found for 
genotype 2 and 3. Seven studies provided information 
regarding baseline IP-10 and SVR. Following the pattern 
regarding rapid virological response all five studies 
examining SVR in relation to baseline IP-10 levels for 
HCV, genotype 1 infected patients showed a significant 
association. Likewise a significant association was seen 
for HCV, genotype 4 infected, while no association was 
found for HCV, genotype 2 and 3 infected. Though only 
two studies examined the assosiation for HCV genotype 4 
infected and HCV genotype 2 and 3 infected respectively. 
CONCLUSION
We found indications of a possible association between 
baseline IP-10 level and virological responses in patients 
with CHC genotype 1 and 4.
Key words: Chronic hepatitis C; Inducible protein-10’s; 
Sustained virological response; Interferon-γ-inducible 
protein-10; CXCL-10; Chemokine; Genotype; Pegylated 
interferon; Ribavirin; Rapid virological response 
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is the first systematic review examining 
the association between baseline levels of interferon-
γ-inducible protein-10 (IP-10) and virological response 
to treatment with pegylated interferon and ribavirin 
among patients chronically infected with hepatitis C 
virus, genotype 1-4. We found a possible correlation 
for genotype 1 and 4 infected patients, indicating that 
baseline IP-10 levels could predict which patients, 
infected with genotype 1 or 4, would have the highest 
likelihood of benefitting from antiviral treatment with 
pegylated interferon and ribavirin. These findings can 
be especially relevant in countries, where treatments 
with direct acting antivirals are not readily applicable.
Neesgaard B, Ruhwald M, Weis N. Inducible protein­10 as a 
predictive marker of antiviral hepatitis C treatment: A systematic 
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INTRODUCTION
Every year 3-4 million individuals are infected with hepa-
titis C virus (HCV) of whom only 20%-35% clear the 
infection, meaning that 2.4-3.2 million individuals remain 
chronically infected, defined as detectable HCV-RNA in two 
consecutive measurements ≥ six months apart. Globally, 
the prevalence of chronic hepatitis C (CHC) is estimated 
to 150 million people, with CHC being the leading cause 
of chronic liver disease[1]. CHC can lead to formation 
of connective tissue (fibrosis) in the liver. However, 
the rate and severity of the inflammation and fibrosis 
vary[2,3]. Though only 5%-20% of HCV infected patients 
develop cirrhosis, these patients have an increased risk 
of developing hepatocellular carcinoma, a condition 
responsible for more than 300000 deaths annually[1]. 
Until recently, the standard of care for CHC was lengthy 
dual therapy with pegylated interferon plus ribavirin (peg-
IFN/RBV), either as 180 μg peg-IFN-α-2a weekly or 
peg-INF-α-2b 1.5 μg/kg per week in combination with 
ribavirin 15 mg/kg per day (minimum 1000 mg daily 
and maximum 1400 mg daily), fixed doses of 1000 mg 
for patients < 75 kg and 1200 mg for patients > 75 kg 
with genotype 1 or 4 or flat dosing of 800 mg daily for 
genotypes 2 and 3 - a treatment with modest success 
rates, severe adverse events and variation in treatment 
response between genotypes[4]. Therefore, a great effort 
has been put into identifying biomarkers to predict rapid 
virological response (RVR), defined as undetectable 
serum HCV-RNA at week four of antiviral treatment, 
and sustained virological response (SVR), defined as 
the undetectable HCV-RNA 24 wk after discontinuing 
antiviral treatment. One of the most promising chemokine 
biomarker candidate is interferon-γ inducible protein-10 
(IP-10). Both intrahepatic IP-10 mRNA and plasma levels 
of IP-10 are elevated in individuals with CHC[5,6], strongly 
indicating that intrahepatic IP-10 is the source of plasma 
IP-10. Several studies have suggested that pretreatment 
levels of IP-10 have the capability to predict RVR and 
SVR[6-9]. In addition, hepatic inflammation and fibrosis 
have been shown to correlate with IP-10 levels[10-12], and 
it has been proposed, that plasma levels of IP-10 can 
predict the risk of fibrosis progression[13]. Later years have 
seen the forthcoming of the new direct acting antivirals 
(DAA), and all current treatment recommendations for 
CHC patients from the European Association for the Study 
of the Liver contain at least one DAA[14]. The current 
DAAs are the NS5B polymerase inhibitor, sofosbuvir, the 
NS3/4A protease inhibitor simeprevir and the NS5A-
replication-inhibitors daclatasvir and ledispavir or the 
so-called 3D regimen containing the dual NS3/4A pro-
tease inhibitors Paritaprevir/Ritonavir, the NS5A inhibitor 
Ombitasvir and the NS5B palm polymerase inhibitor 
Dasabuvir. This has yielded the possibility for treating 
CHC patients with interferon free, all-oral regimens, with 
high SVR-rates and fewer adverse events[14-18]. Despite 
of these great advantages, the cost of DAAs will without 
doubt substantially delay their introduction as standard 
treatment in low and middle-income countries by years to 
come. Moreover, even in high income countries, treatment 
with DAA therapy is reserved for patients with advanced 
liver disease, despite the fact that a majority of patients 
are expected to benefit from the treatment. Therefore, 
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peg-IFN/RBV treatment still has a role to play in treatment 
of patients with CHC, and the need for markers that can 
predict successful treatment outcomes to peg-INF-α/RBV 
are still needed. 
Several studies have independently shown an associa-
tion between virological response and baseline IP-10 
concentrations for CHC patients infected with genotype 1 
and 4[19-21]. However, the association seems to be lacking 
for CHC patients, infected with HCV genotype 2 and 
3[21,22]. Despite this being the case, a systematic review 
to address and clarify the differences in IP-10 properties, 
in relation to the different HCV genotypes, is missing. The 
aim of this systematic review was therefore to examine 
IP-10’s ability to predict RVR and SVR in patients with CHC 
genotypes 1-4 treated with peg-IFN/RBV. We succeeded 
in doing so, with data presented in the following. 
MATERIALS AND METHODS
On initiation of this review a protocol was made and 
registred at the International Prospective Register of 
Systematic Reviews (PROSPERO) - registration number: 
CRD42014008736. Protocol can be found at https://
www.crd.york.ac.uk/PROSPERO/. 
Literature search
Using the search profiles listed in the Appendix Ⅰ in the 
supporting information, suitable literature was identified 
in MEDLINE and EMBASE. The first article sorting was 
performed by rating the article headlines, while the 
second sorting was performed on abstract level. Papers 
passing both sorting rounds were considered for the 
review, and thoroughly scrutinized based on pre-defined 
inclusion and exclusion criteria as listed below. The initial 
search provided 81 articles; 34 in MEDLINE and 47 in 
EMBASE. After the first- and second-sorting, 14 articles 
remained from MEDLINE and 14 articles from EMBASE 
of which 10 were duplicates. One article was found by 
manual searching the references, bringing the total 
number of articles after the third sorting to 19. During 
the third sorting, 11 articles were excluded[6,8,22-30]. This 
left 8 studies for inclusion[7,9,19,21,31-34]. Overveiw of the 
entire sorting proces is shown in Figure 1. 
Inclusion criteria
Case series examining RVR or SVR in relation to 24 or 48 
wk treatment with either 180 μg Peg-IFN-α-2a weekly 
or peg-INF-α-2b 1.5 μg/kg per week in combination with 
ribavirin 15 mg/kg per day (minimum 1000 mg daily and 
maximum 1400 mg daily) or fixed doses of 1000 mg 
for patients < 75 kg and 1200 mg for patients > 75 kg 
or flat dosing of 800 mg daily, in CHC patients infected 
with HCV, genotypes 1 or 4, treatment free for at least 
six months prior to inclusion, with both a baseline IP-10 
level- and HCV-RNA determination, as well as a HCV-
RNA determination four weeks after treatment initiation 
to assess RVR and/or 24 wk after end of treatment to 
assess SVR.
Case series studies examining RVR or SVR, in rela-
tion to 24 wk treatment with either 180 μg Peg-IFN-α-
2a per week or peg-INF-α-2b 1.5 μg/kg per week in 
combination with ribavirin 800 mg daily or fixed doses of 
1000 mg for patients < 75 kg and 1200 mg for patients 
> 75 kg, in CHC patients infected with HCV, genotypes 
2 or 3, treatment free for at least six months prior to 
inclusion, with both a baseline IP-10 level- and HCV-RNA 
determination 4 wk after treatment initiation to assess 
RVR and/or 24 wk after end of treatment to assess SVR.
Exclusion criteria
Liver diseases other than CHC, Co-infection with human 
immunodeficiency virus (HIV), co-infection with hepatitis 
B virus (HBV), alcohol dependency (regular intake of ≥ 
75 g/d), active intravenous drug-use, treatment with 
immunosuppressants or cytostatica and prior treatment 
for CHC within the last 6 mo.
Quality assessment
The quality of the 8 included articles were appraised 
using an 18 point checklist for case series, developed 
using a modified Delphi technique[35]. Each criterion 
can be answered with “yes”, “no” or “partially reported/
unclear”, with the 18 criteria being weighted equally. In 
line with a pilot study conduted testing the assesment 
tool, we choose to rate studies with 14 or more “yes 
responses” as “high-quality studies”, and studies with 
13 or less “yes responses” as “low-quality studies”. No 
studies were excluded on the basis of the criteria scores. 
The full checklist can be found in the Appendix Ⅱ in the 
supporting information. Table 1 shows the sum score 
of the checklist. The baseline demographics regarded 
as important for the appraisel of the studies were: 
Number of patients included, patient ethnicity, patient 
age, male/female ratio, HCV RNA, liver enzyme level 
[alanine transaminase (ALT) or aspartate transaminase 
(AST)], body mass index (BMI), genotype, liver fibrosis 
stage and distribution on interleukin 28B (IL28B) single 
nucleotide polymorphism (SNPs).
RESULTS
Patient baseline demographic
All information was extracted from the articles, no raw 
data was requisitioned. Overall, presentation of baseline 
demographic data was missing in one study. Instead, this 
study provided baseline demographics in the following 
subpopulations: IL28 rs12979860 (CC, CT, TT), rs12980275 
(AA, AG, GG), rs8099917 (TT, TG, GG)[34]. Only baseline 
characteristics for rs12979860 are reported in the review, 
as these were representative for the study population. All 
studies provided baseline information on total number of 
patients included, gender and age. Four studies failed to 
provide BMI[7,9,19,31], and four studies did not supply exact 
information regarding patient ethnicity[7,9,19,32]. Information 
regarding number of patients included, ethnicity, age, 
male/female ratio, and BMI is reported in Table 2. ALT or 
AST values were not reported by two studies[33,34], one of 
these however stated that all patients included had two 
Neesgaard B et al . IP-10 as a predictive marker of antiviral hepatitis C treatment
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serum ALT values above the upper limit of normal within 
6 mo of treatment initiation[34]. Effect on liver parenchyma 
and HCV-RNA load are shown in Table 3. Regarding 
fibrosis stage, four studies used the Ishak score[7,31,33,34], 
two studies used the Scheuer score[9,32], and two studies 
used the Metavir staging system[19,21]. Overview of geno-
type and fibrosis stage is presented in Table 4. Information 
regarding treatment regimens can be found in Table 5. Four 
studies provided information on IL28B SNP distribution. An 
overview of SNPs can be seen in Table 6. 
Rapid virological response
An overview is presented in Table 7. Lagging et al[34] (2011) 
examined IP-10’s ability to predict virological response 
and treatment outcome in 170 patients with genotype 
1, from the DITTO-HCV study group. After six weeks, 
patients were randomized to individualized treatment, 
or continued on the standard combination therapy as 
no sub analysis on SVR for patient receiving therapy, 
corresponding with the review’s inclusion criteria for the 
course of 24-48 wk, was provided. Only results regarding 
RVR are featured in the review. The study found that 
patients obtaining RVR had significantly lower median 
baseline IP-10 levels than patients without a RVR. These 
findings were similar to results reported by Fattovich et 
al[21] that patients infected with HCV, genotype 1, who 
achieved RVR, had a significant lower mean baseline 
IP-10, than those who did not. However, this association 
was not seen for patients infected with HCV genotype 
2 or 3. The study also enrolled genotype 4 infected 
patients, but due to insufficient numbers (n = 15), these 
were excluded. Al-Ashgar et al[19], 2013 studied the 
relationship between IP-10 and virological response in 
patients infected with genotype 4, and showed a trend 
34 articles 
from MEDLINE 
47 articles 
from EMBASE 
20 articles excluded in 
1 and 2 sorting
33 articles excluded 
i 1 and 2 sorting
14 articles from 
MEDLINE after 1 and 
2 sorting performed
14 articles from 
MEDLINE after 1 and 
2 sorting
28 articles left after 1 
and 2 sorting 
10 duplicates
1 article found by hand 
searching references 
19 left after removing 
duplicates 
8 articles enrolled in 
review 
11 Articles excluded in 3 sorting, due to: 
Lack of information regarding treatment doses in relevant subpopulations (n  = 2)
Use of conventional, non-pegylated IFN-α for the treatment of genotype 2 and 3 
patientes, with-out providing a separate SVR analysis for genotype 1 patients (n = 1)
SVR analysis performed on patients, that received individualized treatment 
regimes, not in accordance with inclusion criteria of the review, after 6 wk 
standart treatment (n  = 1)
RVR analysis performed on population already assessed in studies included, SVR 
analysis performed on patients, that received individualized treatment regimens, 
not in accordance with inclusion criteria of the review, after 6 wk standard 
treatment (n  = 2)
Analysis performed on patients with acute HCV infection and early CHC together 
as one group (n  = 1)
Treatment with ribavirin doses that were lower or higher than the doses defined 
in this reveiws inclusion criteria (n  = 2)
Use of differentiated treatment regimens, variable treatment duration, without 
providing a separate SVR-analysis in relevant populations (n  = 1)
Treatment duration not in accordance with this review´s inclusion criteria, without 
relevant subpopulation SVR-analysis, and lack of information regarding treatment 
doses (n  = 1)
Figure 1  Flow chart depicting the sorting of articles. The chart depicts the number of articles found by searching the MEDLINE and EMBASE databases 
04.15.2014, the number of articles excluded during the first and second sorting, the number of duplicates, the number of articles found by manual searching 
references, and the number of articles excluded in the third sorting, with indication of the reason for exclusion. Articles progressing down the chart from the original 
search to final inclusion are marked with green boxes, articles found by manual search are marked with blue boxes, and articles excluded are marked with red boxes. 
SVR: Sustained virological responses; RVR: Rapid virological responses; CHC: Chronic hepatitis C; HCV: Hepatitis C virus.
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towards lower mean baseline IP-10 in patients with RVR, 
than in those without, though the association was not 
significant.
SVR
An overview is presented in Table 8. Following the pattern 
regarding RVR, all five studies examining SVR in relation 
to baseline IP-10 levels for HCV genotype 1 infected 
patients, showed a significant association. 
Apolinario et al[9] enrolled 63 Spanish patients from 
clinical trials and out patient clinics. Forty-three patients 
had genotype 1, while 20 had a non-1 genotype. Among 
the 43 HCV genotype 1 infected patients, mean baseline 
IP-10 levels were significantly lower in patients who 
reached a SVR compared to those who did not. Because 
some of the genotype non-1 infected patients received 
48 wk of therapy, the results for these are not provided in 
Table 7. Diago et al[7] also found a significant association 
between mean baseline IP-10 and SVR for their overall 
population of Spanish patients. An association that 
remained significant, when the analysis was restricted to 
HCV genotype 1 infected patients. The same significant 
association between lower baseline IP-10 and SVR for 
HCV genotype 1 infected, were reported for Italian, 
Croatian and American patients[21,31,33]. An interesting 
aspect of the study by Kurelac et al[33], 2012 was, that 
the greatest difference in IP-10, between patients with a 
SVR vs non-SVR, was seen at treatment week 4, where 
median IP-10 levels were 185 pg/mL (63-518) and 424 
pg/mL (90-815) (P < 0.0001), respectively. Darling 
et al[31] noted, that the significant association between 
baseline IP-10 levels and SVR remained when patients 
were grouped as Caucasian Americans (CA) or African 
Americans (AA) (447 ± 44 pg/mL vs 677 ± 69 pg/mL, 
P < 0.001 and 418 pg/mL ± 35 vs 716 pg/mL ± 55, P 
< 0.001, respectively). Fattovich et al[21] were the only 
ones that reported on HCV genotype 2 and 3 patients. 
As with the results regarding RVR, no association was 
found between SVR and baseline IP-10. Derbala et al[32] 
and Al-Ashgar et al[19] studied HCV genotype 4 infected 
Egyptian and Saudi patients, respectively, and showed 
significantly higher values of baseline IP-10 in non-SVRs 
than in SVRs. Interestingly, a sub analysis, performed 
by Al-Ashgar et al[19] on genotype 4a and 4d, showed 
that this correlation was present for genotype 4d (465.9 
pg/mL ± 349.1 vs 904.9 pg/mL ± 532.1, P < 0.001), 
but not for genotype 4a (564.7 pg/mL ± 288.9 vs 568 
pg/mL ± 384.9, P = 0.300). Derbala et al[32] failed to 
provide information on the exact levels of IP-10, and 
instead provided a graphic depiction, which could not be 
interpreted to adequate results.
DISCUSSION
Several studies have independently shown levels of 
IP-10 to be associated with both RVR and SVR to peg-
IFN/RBV treatment for CHC patients infected with HCV, 
genotype 1 and 4, but not for genotype 2 and 3. We 
conducted this systematic review to assess variation in 
IP-10’s predictive ability for RVR and SVR to peg-INF/
RBV treatment in patients chronically infected with HCV 
genotypes 1-4. 
Our main findings indicate that a correlation exist 
between baseline IP-10 and SVR- and in part for RVR 
- for genotype 1 and possibly for genotype 4, however 
not for genotype 2 or 3. 
Three studies provided information on baseline IP-10 in 
relation to RVR[19,21,34]. Studies reporting on HCV, genotype 
1 infected patients, found significant lower baseline IP-10 
values in patients achieving RVR compared to those who 
did not[21,34]. Only a trend, failing to reach significance, was 
described between baseline IP-10 and RVR in genotype 
4 infected patients[19] and no significant relation was 
found in relation to genotype 2 or -3[21]. Seven studies 
provided information on baseline IP-10 in relation to 
SVR[7,9,19,21,31-33]. All five studies reporting on HCV genotype 
1 infected patients[7,9,21,31,33] found significantly lower 
IP-10 levels of SVR than non-SVR. Diago et al[7] did not 
provide separate results for the group of genotype non-1 
patients included, which was surprising, as three quarters 
of the patients were infected with HCV, genotype 1, and 
could very well be the reason for finding a significant 
association in the overall population, when all genotypes 
were analyzed together. In line with this, Apolinario 
et al[9] stated that no associations was found for their 
genotype non-1 group. However lacking differentiation 
into sub genotypes, compromise the value of information, 
especially as no association were found for HCV, genotype 
2 or 3 infected[21], and both studies reporting on genotype 
4 infected patients[19,32] found significant lower baseline 
IP-10 level in their populations, when comparing patients 
achieving SVR vs non-SVR. It should be noted, that while 
Fattovich et al[21] considered two-sided P-values < 0.05 as 
statistical significant, only results of statistical tests with a 
P-value < 0.01 were considered of interest, because of the 
multiple comparisons between subjects with and without 
SVR. Therefore IP-10 was not considered to be associated 
with SVR, for HCV genotype 3 infected individuals, even 
though the p-value was found to be 0.02.
One study observed that the greatest difference in 
IP-10 levels was found at week 4. Patients, who at this 
Ref. Yes 
response
No 
response
Partiel 
reported/ 
unclear
Assessment
Fattovich et al[21] 16 2 0 High-quality
Diago et al[7] 15 2 1 High-quality
Apolinario et al[9] 14 2 2 High-quality
Darling et al[31] 14 1 3 High-quality
Lagging et al[34] 14 3 1 High-quality
Al-Ashgar[19] 13 3 2 Low-quality
Derbala et al[32] 13 2 3 Low-quality
Kurelac et al[33] 12 3 3 Low-quality
Table 1  Overview of the modified Delphi, 18-point quality 
assessment checklist for studies included in the review
Studies was ranked as high quality if the provided ≥ 14 “yes” answers, or 
low quality if they provided ≤ 13 “yes” answers. 
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point had IP-10 levels higher than 250 pg/mL, had a 
40-fold risk of not reaching SVR compared to patients 
with IP-10 levels lower than 250 pg/mL[33]. This might 
indicate, that IP-10 levels at treatment week 4, could 
be used to assess if peg-INF/RBV treatment should be 
discontinued or not in genotype 1 patients - and perhaps 
could also be used to evaluate the need for adjacent DAA 
treatment (i.e., using a 4 wk lead in phase with peg-
INF/RBV treatment before apprising the need for DAAs). 
However, the small number of patients participating calls 
for caution when interpreting these results, and further 
studies of IP-10 levels at treatment week 4 should be 
encouraged. 
One study[31] showed that the correlation between 
baseline IP-10 and SVR remained significant even when 
the population was grouped according to ethnicity (P < 
0.001). The latter is interesting as AA ethnicity is otherwise 
considered an unfavorable prognostic factor for obtaining 
SVR[36-38], and might imply that IP-10 could help aid the 
decision as to whom would have the greatest potential 
benefit from peg-INF/RBV treatment regardless of 
ethnicity. In this context it is interesting that it has pre-
viously been shown that HCV infected AA had higher IP-10 
levels than corresponding CA patients, while uninfected AA 
had IP-10 levels similar to uninfected CA[28]. The effect of 
race on Interferon Stimulated Genes, once at the stage 
of CHC, should therefore be examined further. 
Findings, regarding SVR for HCV genotype 2 and 3, 
followed the same pattern as the results for RVR with no 
association between baseline IP-10 and SVR present for 
genotype 2 or 3[21]. Supporting our findings, this lacking 
correlation in patients with HCV genotype 2 and 3, has 
also been shown when treating patients with standard 
and low (90 μg once weekly) peg-INF/RBV regimens[22]. 
As mentioned, a significant correlation between IP-10 
and SVR was reported by both studies, including HCV 
genotype 4 infected patients[19,32]. One of these[19] also 
performed differentiated analyses on HCV genotype 4 
Ref. Patients Mean age BMI Ethnicity
Males Total (n ) (yr) (kg/m2) Caucasian African American Asian
Apolinario et al[9]   40   63     41 (± 9.3)5 Information not provided Information not provided6
1Lagging et al[34] 169  2522  2529
IL28B rs12979860 CC   64   93    41.6 (± 10.1)5 25.1 (± 3.6)5
IL28B rs12979860 CT   77 123  41.9 (± 9.5)5 25.0 (± 3.5)5
IL28B rs12979860 TT   28   36    41.9 (± 11.4)5 25.0 (± 3.5)5
Diago et al[7]   77 137     42 (± 9.7)5 Information not provided Information not provided 
Fattovich et al[21] 133  2263    46 (± 11)5 24.7 (± 3.8)5 226
Kurelac et al[33]   17   46    41.5 (± 12.4)5     23.7 (21.9-25)4   46
Darling et al[31] 176 272  48.4 (± 7.4)5 Information not provided 138 134
Darbala et al[32] 144 159  46.47 (± 8.83)5 30.18 (± 5.05)5 Information not provided7
Al-Ashgar et al[19]   41   64    38.7 (± 11.5)5 Information not provided Information not provided8
1Study did not provide baseline characteristics for their entire population, but instead provided baseline demographics in accordance with IL-28 genotype 
(only baseline characteristics for rs12979860 are reported in the review, as these were representative for the study population); 2253 was reported to be 
enrolled, however when adding the males and female patients, it sums to 252; 3Only 226 out of 280 patients had serum available for iP-10 testing; 4Median 
(25-75 percentiles); 5Mean (SD); 651 patients from clinical trials had Spanish nationality; 7Egyptian nationality; 8Saudi nationality; 995% of the original DITTO 
patient population were Caucasian.  BMI:  Body mass index.
Table 2  Baseline total patient number, number of male patients, mean age, body mass index and ethnicity for the 8 included studies
Ref. HCV-RNA Liver enzyme level
     High viral load    Low viral load All patients AST ALT
n Limit n Limit
Apolinario et al[9]   28 ≥ 6.3 log IU/mL5 35  < 6.3 log IU/mL5 118 IU/L (± 64) $
1Lagging et al[34] 
   IL28B rs12979860 CC 6.3 log IU/mL (± 0.8)3 Information not provided
   IL28B rs12979860 CT 6.1 log IU/mL (± 0.7)3
   IL28B rs12979860 TT 5.9 log IU/mL (± 0.8)3
Diago et al[7]   85 ≥ 5.7 log IU/mL5 52 < 5.7 log IU/mL5 117.2 IU/L (± 81.6)3
Fattovich et al[21] 147 ≥ 5.6 log IU/mL5 5.74 log IU/mL (± 0.9)3,5 92 IU/L (± 78)3
Kurelac et al[33] 5.55 log IU/mL (5.52-6.1)2,5 Information not provided
Darling et al[31] 6.66 log IU/mL (± 6.76)3,5 90.9 IU/L (72.9)3
Darbala et al[32] 4.95 log IU/mL (3.6-5.63)4,5  38 IU/L (27-51)4 51 IU/L (34-87)4
Al-Ashgar et al[19]   45 ≥ 5.78 log IU/mL 19 < 5.78 log IU/mL5 67.5 IU/L (43.5-106.8)2 56.0 IU/L (32.0-86.0)2
1Lagging et al provided baseline demographics in accordance with IL-28 genotype (only baseline characteristics for rs12979860 are reported in the review, 
as these were representative for the study population); 2Median (25-75 percentiles); 3Mean (SD); 4Median (IQR); 5Recalculated into log IU/mL. HCV-RNA is 
shown as number of patients with high or low viral load or as the mean or median for the entire population. Depending of the presentation in the original 
article, levels of ALT, AST or both are shown. HCV:  Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase.
Table 3  Hepatitis C virus-RNA and patient liver enzyme status for the 8 included studies
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subtypes, 4a and 4d, showing a significant association only 
for the latter (P = 0.330 and P < 0.001, respectively). It 
would have been interesting to examine if this was also the 
case for RVR, as it could be speculated that the association 
between baseline IP-10 and RVR in HCV genotype 4 
infected patients failed to show significance, because both 
subtype 4a and 4d were analyzed as a whole. Therefore, 
subsequent studies making RVR and SVR assessments 
should be encouraged to perform differential analysis on 
individual viral subtypes, in order to uncover more specific 
associations. The setup for this study, did not allow us to 
investigate, what specific mechanisms account for the 
differences in correlation between baseline IP-10 and HCV 
genotype 1 and 4 compared with HCV genotype 2 and 3. 
However it is of great interest that these differences occur, 
and should be investigated further. Inversely patients 
infected with HCV genotype 2 or 3 generally has a more 
favorable response to treatment with PEG-IFN and RBV. 
Therefore, in a clinical setting the underlying mechanism 
might not be relevant, as genotype 2 and 3 patients 
would readily be treated, whereas clinitians might be more 
reluctant to initiate peg-INF treatment to genotype 1 and 
4 - infected individuals and here IP-10 levels might help to 
show which patients should undergo treatment. 
This review focused on the association between pre-
treatment IP-10 levels and virological responses. However, 
IL28B SNPs should be addressed when considering IP-10, 
as they are strongly linked with treatment response to 
Peg-INF/ RBV[39-45]. Especially are homozygote genotypes 
at markers rs8099917 (TT), rs12979860 (CC) and 
rs12980275 (AA) associated with a favorable outcome to 
treatment. While IL28B polymorphisms were not found to be 
predictive for treatment response in HCV genotype 2 and 
3 infected individuals by Fattovich et al[21], pretreatment 
IL28B polymorphisms, HCV-RNA- and IP-10 levels 
independently predict RVR in HCV genotype 1 infected 
individuals, with RVR in turn being the strongest predictor 
of SVR. Combining the IL28B polymorphisms and HCV-
Ref. Genotype (n) Method Liver fibrosis stage 
1 2 3 4 0 1 2 3 4 5 6
Apolinario et al[9]   43 20 Scheuer score   28 35
Lagging et al[34]4  1701  231  491    111 Ishak score   11   61 65 30 15 20 14
IL28B rs12979860 CC   44 13 33     3     3   18 27 11   5 12   5
IL28B rs12979860 CT   96   7 15     5     7   35 27 17   7   6   6
IL28B rs12979860 TT   30   3   1     3     1     8 11   2   3   2   3
Diago et al[7] 103   9 25 Ishak score 106 31
Fattovich et al[21]   92 87 47 Metavir2 121 21
Kurelac et al[33]   46 Ishak   34 12
Darling et al[31] 272 Ishak 220 52
Darbala et al[32] 159 Scheuer score 109 50
Ashgar et al[19]   64 Metavir    343  10 3
1Baseline information for the sub analysis of IL28 12979860. Two hundred and fifty-two patients are reported to be enrolled, however adding the genotypes 
yields 253 patients. Likevise biopsies from 228 patients are described, however when adding the Ishak scores only yields 216 patients; 2Biopsies only 
available for 142 patients; 3Histology available for 44 patients; 4Lagging et al provided baseline demographics in accordance with IL-28 genotype (only 
baseline characteristics for rs12979860 are reported in the review, as these were representative for the study population). A box stretching over two - or 
more genotypes or fibrosis stage, indicates that the number refers to the combined group. 
Table 4  Genotype and liver fibrosis stage for the 8 included studies
Ref. Genotype Duration Interferon treatment Ribavirin treatment
Apolinario et al[9] Multi-centerpatients 1 48 wk 180 μg peg-INF-α-2a once weekly 800 mg per day or 1000 mg < 75 kg, 1200 
mg > 75 kgNon-1 24-48 wk
Out patiens 1 48 wk peg-INF-α2b 1.5 μg/kg per week 1000-1200 mg per day
Non-1 24 wk
Lagging et al[34] 1 6 wk1 180 μg peg-INF-α-2a once weekly 1000 mg < 75 kg, 1200 mg > 75 kg per day
Diago et al[7] 1 48 wk peg-INF-α-2b 1.5 μg/kg per week or 180 
μg peg-INF-α-2a/week
1000 mg < 75 kg, 1200 mg > 75 kg per day
Non-1 24 wk
Fattovich et al[21] 1 and 4 48 wk peg-INF-α-2b 1.5 μg/kg per week or 180 
μg peg-INF-α-2a/week
800-1200 mg per day
2 and 3 24 wk
Kurelac et al[33] 1 48 wk peg-INF-α-2b 1.5 μg/kg per week Weight based ribavirin treatment2
Darling et al[31] 1 48 wk 180 μg peg-INF-α-2a once weekly 1000-1200 mg per day
Derbala et al[32] 4 48 wk Peg-IFN once weekly3 1000 mg < 75 kg, 1200 mg > 75 kg per day
Al-Ashgar[19] 4 48 wk 180 μg peg-INF-α-2a once weekly 1000 mg < 75 kg, 1200 mg > 75 kg
1After 6 wk, patients were randomized to differentiated treatment regimes; 2No further information on ribavirin treatment was provided; 3No further 
information on the subtype of peg-IFN was provided. Apolinario et al[9] feature patients from both an outpatient clinic as well as patients from two 
multicenter trials receiving different treatment regimens, illustrated by the segregation in the genotype column. peg-IFN: Pegylated interferon.
Table 5  Overview of the treatment regimens for pegylated interferon in combination with ribavirin, for the 8 studies included, in 
relation to dose and duration
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RNA yielded a specificity of 98% but a low sensitivity 
of 39%. By including IP-10 values in the equation, the 
sensitivity and the negative predictive value was raised 
from 81% to 94%, however lowering the positive 
predictive value from 87% to 76%. This is consistent with 
other findings in HCV genotype 1 infected, homozygous 
carriers of the favorable IL28B SNPs, with low IP-10 level, 
which also significantly predicted a first phase decline of 
HCV RNA, which translated into increased rates of RVR 
and SVR[30]. While the two latter studies was carried out 
solely on Caucasian patients infected with HCV genotype 1, 
the additive predictive effect has also been shown for both 
HCV genotype 1 infected AA and CA patients[31], and HCV 
genotype 4 infected patients[32], respectively. Although 
low in numbers, these results could indicate, that both 
variables should be considered in a clinical context, before 
initiating treatment with Peg-INF/RBV in patients infected 
with HCV genotype 1 or 4. Further studies examining the 
association in HCV genotype 2 and 3 infected patients 
should be encouraged.
Conducting a systematic review with clear and strin-
gent in- and exclusions criteria, is an obvious strength of 
this study, ensuring homogeneity between the studies 
included, hereby allowing an unbiased assessment of 
the current evidence. Another strength of our study was 
that we assessed the quality of the studies included, 
and provided a detailed declaration of the studies aim, 
method - including treatment regimens and duration, as 
well as baseline patient demographics for the individual 
studies - supplying a solid ground for interpreting the 
results put forth. Although some authors recommend 
the use of quality assesments, other consider them 
misleading[46], and there remains uncertainties about 
the relationship between methodology, validity and the 
use of sum scores to judge the quality of studies[47]. 
Therefore we chose not to exclude any articles based on 
their quality score (e.g., high quality or low quality), but 
instead presented the ratings of the studies in the review 
to serve as an objective guide to interpret the review’s 
results, rather than a tool for selecting studies for the 
review. As seen by the exclusion criteria, we wished to 
eliminate the possible uncertainties that could arise by 
including studies treating HIV/HCV - or HBV/HCV co-
infected patients. Therefore, it should be mentioned that 
even though there was no indication towards inclusion of 
co-infected patients, three of the included studies, based 
in the United States, Croatia and Egypt, contained no 
clear exclusion criteria for HIV- or HBV- infection[31-33].
Only a limited number of articles fulfilled the in- and 
exclusion criteria to be assessed in this review. Hence, 
more work is needed to establish a sufficient ground 
for final conclusions to be made. Further, there was an 
overweight of studies that addressed the association 
between SVR and baseline IP-10 in CHC patients infected 
Ref. Genotype (n) rs12979860 rs12980275 rs8099917 rs11881222
CC CT TT AA AG GG TT TG GG AA AG GG
Lagging et al[30]   1 (253) 93 123 37 101 115 37 153 90 10
Fattovich et al[21] 1 (92) 33   44 15   33   45 14   49 38   5
2 (87) 34   43 10   34   42 11   47 34   6
3 (47) 25   21   1   25   20   2   34 13   0
Darling et al[31]   1 (201) 63 103 44
Derbala et al[32]   4 (159) 57   77 25   96 55   8 64 75 20
Genotype column indicates specific genotype, and total number of patients with the specific genotype. Each marker column is divided into allelic 
distribution for the IL28B SNP genotype. SNP:  Single nucleotide polymorphism.
Table 6  Overview of the marker distribution, in the four studied that supplied information on interleukin 28B single nucleotide 
polymorphism
Ref. Patients 
(n )
IP-10 measurement method Genotype 
(n)
Baseline IP-10 concentration, grouped by rapid virological 
response (pg/mL)
Overall RVR (n)
RVR Non-RVR P -value RVR Non-RVR
Lagging et al[34] 170 ELISA (Quantikine, R and D 
systems, Minneapolis, MN, 
United States)
  1 (170) 222 401 P < 0.01 (median) 33 137
1Fattovich et al[21] 226 ELISA (Quantikine, R and D 
systems, Minneapolis, MN, 
United States)
1 (92)   2.4 (± 0.28)    2.6 (± 0.25)       P < 0.01 (log mean ± SD) 172 108
2 (87) 2.38 (± 0.31)    2.3 (± 0.30)       P > 0.05 (log mean ± SD)
3 (47) 2.45 (± 0.23)  2.48 (± 0.39)       P > 0.05 (log mean ± SD)
Al-Ashgar et al[19]   64 ELISA (Quantikine, R and D 
systems, Minneapolis, MN, 
United States)
4 (64) 483.9 (± 261.6) 609.9 (±424.3) P > 0.05 (mean ± SD)   12   52
1Entire patient population was 280, genotype 4 infected were removed from the analyses, and IP-10 results was available for 226 patients. IP-10: Inducible 
protein-10; RVR: Rapid virological response.
Table 7  Overview of rapid virological response in the 3 studies providing information on baseline inducible protein-10’s, and 
hepatitis C virus RNA levels at week 4
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with HCV genotype 1, whereas there was only a small 
fraction addressing the association between SVR and 
baseline IP-10 for genotype 2, 3 and 4, as well as studies 
examining the relationship between RVR and baseline 
IP-10 constituting an insufficient base for assessing 
baseline IP-10’s predictive ability in these regards. 
In this systematic review, we found correlations between 
baseline IP-10 levels and SVR in patients chronically 
infected with HCV genotype 1 and 4, while no such 
association was found for patients infected with HCV 
genotype 2 or 3. Likewise, we found indications of a 
possible correlation between baseline IP-10 and RVR 
for HCV genotype 1 infected patients, while no such 
association were found for HCV genotype 2 or 3 patients, 
and only a trend was found for HCV genotype 4 infected 
patients. However, the amount of information regarding 
baseline RVR for genotypes 1-4, and SVR’s relation with 
baseline IP-10 for genotypes 2, 3 and 4 were insufficient 
for final conclusions.
COMMENTS
Background
Until recently, the standard of care for chronic hepatitis C (CHC) patients was 
lengthy dual therapy with pegylated interferon plus ribavirin (peg-IFN/RBV), a 
treatment with modest success rates, severe adverse events and variation in 
treatment response between hepatitis C virus (HCV) genotypes. Therefore, 
efforts to identifying biomarkers that can predict virological responses to treatment 
have been made. Interferon-γ inducible protein-10 (IP-10) is one such promising 
marker, with several studies independently showing an association between 
virological response and baseline IP-10 concentrations for CHC patients infected 
with HCV genotype 1 and 4. However, the association seems to be lacking for 
CHC patients, infected with HCV genotype 2 and 3. 
Research frontiers
IP-10 has been shown to be expressed at higher levels in HCV genotype 1 
infected CHC patients with moderate to severe fibrosis compered to patients 
with mild or non fibrosis. Therefore, studies are being made to examine if this 
correlation is also found in HCV genotype 2 and 3 infected CHC patients. 
In addition to this, examinations of baseline IP-10 ability to predict fibrosis 
progression in CHC patients are pending. IP-10 research in relation to CHC is 
therefore expanding from the possible correlation between virological response to 
treatment with peg-INF/RBV at baseline, to also include fibrosis score at baseline 
and fibrosis progress over time. 
Innovations and breakthroughs
Despite the work done so far to correlate IP-10 levels to treatment response, 
this is to our knowledge, the fist systematic review to address and clarify the 
differences in IP-10 properties, in relation to the different HCV genotypes and 
virological response. The authors found indications of correlations between 
baseline IP-10 levels and SVR in CHC patients infected with HCV genotype 1 and 
4, but not in patients infected with HCV genotype 2 or 3. Likewise, the authors 
found indications of a possible correlation between baseline IP-10 and RVR for 
HCV genotype 1 infected patients, while no such association were found for HCV 
genotype 2 or 3 patients, and only a trend was found for HCV genotype 4 infected 
patients. 
Applications
Despite of the great advantages with the new treatment options with direct 
acting antivirals (DAA), the cost of DAAs will without doubt substantially delay 
their introduction as standard treatment in low and middle-income countries by 
Ref. Patients 
(n )
IP-10 measurement method Genotype 
(n)
Baseline IP-10 concentration, grouped by sustained virological 
response (pg/mL)
Overall SVR
SVR Non-SVR P -value SVR Non-SVR
Apolinario et al[9]   63 ELISA (OptEIA, 
Pharmingen, San Diego, CA, 
United States)
  1 (43)   245 (± 154)   381 (± 138)   P < 0.05 (mean ± SD)   36   27
Diago et al[7] 137 ELISA (Human 
immunoassay kit; BioSource 
Europe SA, Nivelles, 
Belgium 
    1 (103)      347 (± 197.4)   500.6 (± 311.2)   P < 0.01 (mean ± SD)    792    582
    1 (103)   332.4 (± 222.1)   476.8 (± 305.3)   P < 0.01 (mean ± SD)
2 (9)
  3 (25)
1Fattovich et al[21] 226 ELISA (Quantikine, R and D 
systems, Minneapolis, MN,  
United States )
  1 (92) 2.47 ± 0.23 2.65 ± 0.28       P < 0.001 (log mean ± SD)  2092    712
  2 (87) 2.37 ± 0.31 2.33 ± 0.35         P > 0.05 (log mean ± SD)
  3 (47) 2.42 ± 0.21 2.67 ± 0.46        P < 0.05a (log mean ± SD)
Kurelac et al[33]   46 ELISA (Quantikine, R and D 
systems, Minneapolis, MN,  
United States )
  1 (46)      185 (63-518)    395.5 (111-926)     P < 0.0001 (median, range)   26   20
Darling et al[31] 272 ELISA (Quantikine, R and D 
systems, Minneapolis, MN,  
United States )
    1 (272) 437 (± 31) 704 (± 44) P < 0.001 (mean ± SD) 157 115
Derbala et al[32] 159 Luminex, Cytokine 
multiplex immunoassay kit 
(Merck Millipore, Billerica, 
MA,  United States)
    4 (159) Exact data not provided, only 
graphic presentation
   P < 0.001 (median, IQR)   98   61
Al-Ashgar et al[19]   64 ELISA (Quantikine, R andD 
systems, Minneapolis, MN,  
United States )
  4 (64)      462 (± 282.6)   840.4 (± 490.6)   P < 0.01 (mean ± SD)   41   23
Table 8  Overview of sustained viral response in the 8 studies providing information on baseline inducible protein-10’s, and hepatitis 
C virus-RNA levels 24 wk after end-of- treatment
1Entire patina population was 280, genotype 4 removed from the analyses, and IP-10 results was available for 226 patients Note that M. Derbala et al did 
not provide written specification on IP-10 levels for SVR compared to non-SVR, and only supplied a graphic depiction, which could not be interpreted to 
adequate results; 2SVR for the entire population. aP = 0.02. Only the results of statistical tests with a P value < 0.01 were considered of interest, because of 
the multiple comparisons between subjects with and without SVR. SVR:  Sustained viral response; IP-10: Inducible protein-10.
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years to come. In addition, DAA in high-income countries is still reserved for 
patients with advanced liver disease. Therefore, peg-IFN/RBV treatment still 
has a role to play in treatment of patients with CHC. Their findings of a possible 
correlation between baseline IP-10 levels and SVR in CHC patients infected 
with HCV genotype 1 and 4 but not for genotypes 2 and 3 could be beneficial in 
a clinical setting. Genotype 2 and 3 patients would readily be treated, as these 
patients generally have a favorable outcome to peg-IFN/RBV compared to 
genotype 1 and 4 infected individuals. In such patients, IP-10 levels might help 
to show which patients would have the best prognosis for a positive outcome to 
treatment.
Terminology
Interferon-γ inducible protein-10, more commonly denoted IP-10 or CXCL10, 
is a non-ELR-CXC chemokine, binding to the CXC-receptor-3. It functions as a 
chemotactic, attracting T lymphocytes and NK cells to the site of inflammation. 
Within the liver, IP-10 mRNA is produced by hepatocytes in inflammatory areas, 
and both intrahepatic IP-10 mRNA - and plasma levels of IP-10 are elevated in 
individuals with CHC, indicating that intrahepatic IP-10 is the source of plasma 
IP-10. The hypothesis therefore is that IP-10 can function as proxy for the level 
of liver inflammation, which in turns lead to fibrosis formation.
Peer-review
This is a well written and comprehensive systemic review to explore the asso-
ciation between baseline levels of interferon-γ-inducible protein-10 and virological 
response to treatment with pegylated interferon and ribavirin among patients 
chronically infected with hepatitis C virus, genotype 1-4.
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